Using Longitudinal Endpoint Data to Anticipate Study Complexity
When it comes to unnecessary protocol complexity, the cracks often show up later. Amendments. Delayed activation. Added site burden. By
When it comes to unnecessary protocol complexity, the cracks often show up later. Amendments. Delayed activation. Added site burden. By
Clinical research decisions are only as sound as the records supporting them, and that soundness begins with data integrity: the
In fall 2026, the Advarra-facilitated Site-Sponsor Consortium will release a white paper on reducing redundant site training through competency-based, role-based, and reusable training models while aligning with international regulatory guidelines.
A leading U.S.-based academic medical center sought specialized support to navigate its five-year AAHRPP reaccreditation cycle after leadership turnover created
Site-Sponsor Consortium Building shared industry standards through collaboration The Site-Sponsor Consortium is an invitation-only forum that brings together influential leaders
In fall 2026, the Advarra-facilitated Site-Sponsor Consortium will release a white paper on reducing redundant site training through competency-based, role-based, and reusable training models while aligning with international
Rachel Garrett’s career in clinical research has come full circle. After starting her journey at Schulman IRB in 2008, stepping
Clinical trial monitoring (CTM) and auditing are both essential quality management activities, but they serve distinct purposes throughout the research
What impact will advancements in artificial intelligence (AI) have on national security and global public health issues, particularly when it
Understanding the regulatory foundation behind translated informed consent documents and why many institutional review boards (IRBs) require certificates or attestations of translation.
ACRO Global Summit brings together senior regulators and industry leaders from around the world to discuss the evolving regulatory landscape
Gene therapies and gene-based therapeutics are giving way to a new era of interventional genetics. Integrated ethics review and biosafety review have developed into an operational advantage to facilitate this